Literature DB >> 33966318

Hepatic macrophages: Key players in the development and progression of liver fibrosis.

Da Cheng1, Jin Chai2, Huiwen Wang1, Lei Fu1,3, Shifang Peng1,3, Xin Ni3,4.   

Abstract

Hepatic fibrosis is a common pathological process involving persistent liver injury with various etiologies and subsequent inflammatory responses that occur in chronic liver diseases. If left untreated, liver fibrosis can progress to liver cirrhosis, hepatocellular carcinoma and eventually, liver failure. Unfortunately, to date, there is no effective treatment for liver fibrosis, with the exception of liver transplantation. Although the pathophysiology of liver fibrosis is multifactorial and includes the activation of hepatic stellate cells, which are known to drive liver fibrogenesis, hepatic macrophages have emerged as central players in the development of liver fibrosis and regression. Hepatic macrophages, which consist of resident macrophages (Kupffer cells) and monocyte-derived macrophages, have been shown to play an intricate role in the initiation of inflammatory responses to liver injury, progression of fibrosis, and promotion of fibrosis resolution. These features have made hepatic macrophages uniquely attractive therapeutic targets in the fight against hepatic fibrosis. In this review, we synthesised the literature to highlight the functions and regulation of heterogeneity in hepatic macrophages. Furthermore, using the existing findings, we attempt to offer insights into the molecular mechanisms underlying the phenotypic switch from fibrogenic macrophages to restorative macrophages, the regulation of heterogeneity, and modes of action for hepatic macrophages. A better understanding of these mechanisms may guide the development of novel anti-fibrotic therapies (eg macrophage subset-targeted treatments) to combat liver fibrosis in the future.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Kupffer cell; inflammation; liver fibrosis; macrophage

Year:  2021        PMID: 33966318     DOI: 10.1111/liv.14940

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  12 in total

Review 1.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

Review 2.  Emerging therapeutic potential of adeno-associated virus-mediated gene therapy in liver fibrosis.

Authors:  Fang-Tian Bu; Peng-Cheng Jia; Yan Zhu; Ya-Ru Yang; Hong-Wu Meng; Yi-Hui Bi; Cheng Huang; Jun Li
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-22       Impact factor: 5.849

Review 3.  Crosstalk Between Autophagy and Innate Immunity: A Pivotal Role in Hepatic Fibrosis.

Authors:  Li Chen; Desong Kong; Siwei Xia; Feixia Wang; Zhanghao Li; Feng Zhang; Shizhong Zheng
Journal:  Front Pharmacol       Date:  2022-05-17       Impact factor: 5.988

4.  M2 macrophage-derived exosomal microRNA-411-5p impedes the activation of hepatic stellate cells by targeting CAMSAP1 in NASH model.

Authors:  Zhiping Wan; Xiaoan Yang; Xiaoquan Liu; Yinfang Sun; Piaojian Yu; Fen Xu; Hong Deng
Journal:  iScience       Date:  2022-06-14

5.  Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy.

Authors:  Pil Soo Sung; Dong Jun Park; Pu Reun Roh; Kyoung Do Mun; Sung Woo Cho; Gil Won Lee; Eun Sun Jung; Sung Hak Lee; Jeong Won Jang; Si Hyun Bae; Jong Young Choi; Jonghwan Choi; Jaegyoon Ahn; Seung Kew Yoon
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

Review 6.  Pathogenesis of Liver Fibrosis and Its TCM Therapeutic Perspectives.

Authors:  Yang Nan; HongChan Su; XiaoMei Lian; Juan Wu; SuJie Liu; PingPing Chen; ShuMin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-28       Impact factor: 2.650

Review 7.  The versatility of macrophage heterogeneity in liver fibrosis.

Authors:  Chun-Chen Gao; Jian Bai; Hua Han; Hong-Yan Qin
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

Review 8.  Pathogenesis from Inflammation to Cancer in NASH-Derived HCC.

Authors:  Simiao Yu; Jingxiao Wang; Haocheng Zheng; Ruilin Wang; Nadia Johnson; Tao Li; Ping Li; Jie Lin; Yuan Li; Jin Yan; Ying Zhang; Zhenyu Zhu; Xia Ding
Journal:  J Hepatocell Carcinoma       Date:  2022-08-26

Review 9.  Is the Macrophage Phenotype Determinant for Fibrosis Development?

Authors:  Lluis Lis-López; Cristina Bauset; Marta Seco-Cervera; Jesús Cosín-Roger
Journal:  Biomedicines       Date:  2021-11-23

10.  A Unique Immune-Related Gene Signature Represents Advanced Liver Fibrosis and Reveals Potential Therapeutic Targets.

Authors:  Pil-Soo Sung; Chang-Min Kim; Jung-Hoon Cha; Jin-Young Park; Yun-Suk Yu; Hee-Jung Wang; Jin-Kyeoung Kim; Si-Hyun Bae
Journal:  Biomedicines       Date:  2022-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.